5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine
|
- ₹0
- Product name: 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine
- CAS: 1225037-39-7
- MF: C17H20F3N7O2
- MW: 411.38
- EINECS:-0
- MDL Number:MFCD28902193
- Synonyms:5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine;PI3K-IN-2;PQR309;Bimiralisib;PQR309 Bimiralisib;CS-2024;PQR309;PQR 309;PQR-309;Bimiralisib (PQR309)(free base)
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|
Properties
Boiling point :643.7±65.0 °C(Predicted)
Density :1.418±0.06 g/cm3(Predicted)
storage temp. :Store at -20°C
solubility :DMSO:22.0(Max Conc. mg/mL);53.48(Max Conc. mM)
DMF:10.0(Max Conc. mg/mL);24.31(Max Conc. mM)
Ethanol:2.0(Max Conc. mg/mL);4.86(Max Conc. mM) form :A crystalline solid
pka :4.92±0.10(Predicted)
color :White to gray
Density :1.418±0.06 g/cm3(Predicted)
storage temp. :Store at -20°C
solubility :DMSO:22.0(Max Conc. mg/mL);53.48(Max Conc. mM)
DMF:10.0(Max Conc. mg/mL);24.31(Max Conc. mM)
Ethanol:2.0(Max Conc. mg/mL);4.86(Max Conc. mM) form :A crystalline solid
pka :4.92±0.10(Predicted)
color :White to gray
Safety Information
| Symbol(GHS): |
|
||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | ||||||||||||||||||||||||||||||||||
| Hazard statements: |
|
||||||||||||||||||||||||||||||||||
| Precautionary statements: |
|
Description
Bimiralisib is a potent and orally bioavailable inhibitor of phosphatidylinositol 3-kinases (PI3Ks; IC50s = 33, 661, 708, and 451 nM for PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, respectively) and the mammalian target of rapamycin (mTOR; IC50 = 89 nM). It is selective for these kinases over a panel of cell surface and nuclear receptors, membrane channels, transporters, kinases, proteases, and phosphodiesterases at a concentration of 10 μM. Bimiralisib has anticancer activity with an average GI50 value of 0.7 μM across the National Cancer Institute (NCI) 60 human cancer cell line panel. In vivo, bimiralisib (5-15 mg/kg) reduces tumor growth in a dose-dependent manner in a PC3 prostate cancer mouse xenograft model. Formulations containing bimiralisib are under clinical investigation for the treatment of relapsed and refractory lymphoma and advanced solid tumors.Related product price
- 196868-63-0
₹17860-19116.95 - PPQ-102
₹21460
Suppliers and manufacturers
career henan chemical co
A.J Chemicals
CLEARSYNTH LABS LTD.
ATK CHEMICAL COMPANY LIMITED
TargetMol Chemicals Inc.
Zhejiang J&C Biological Technology Co.,Limited
InvivoChem
ShenZhen Trendseen Biological Technology Co.,Ltd.
LEAPCHEM CO., LTD.
Aladdin Scientific
₹1.00 /1KG
5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine CAS:1225037-39-7
5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine CAS:1225037-39-7